Glaucoma is a common eye condition that affects millions of people worldwide. It is a progressive disease that damages the optic nerve, leading to vision loss and blindness if left untreated. One of the primary risk factors for glaucoma is high intraocular pressure (IOP), which can damage the optic nerve over time. While there are several treatments available for glaucoma, including eye drops, laser therapy, and surgery, researchers are constantly exploring new ways to manage the condition. One such innovation is MediPrint’s contact lens with drug release capability, which has shown promising results in lowering IOP in patients with glaucoma.
MediPrint is a biotechnology company that specializes in 3D printing of medical devices. Their contact lens with drug release capability is designed to deliver medication directly to the eye, providing sustained release of the drug over an extended period. The lens is made from a biocompatible material that is safe for use in the eye and can be customized to fit each patient’s unique eye shape.
In a recent study published in the journal Biomaterials, researchers tested the efficacy of MediPrint’s contact lens in lowering IOP in patients with glaucoma. The study included 12 patients with open-angle glaucoma, a common form of the disease. Each patient wore the contact lens for 24 hours, during which time the lens released a medication called latanoprost, which is commonly used to lower IOP in glaucoma patients.
The results of the study were promising. The researchers found that the contact lens with drug release capability significantly lowered IOP in all 12 patients. The average reduction in IOP was 5.4 mmHg, which is comparable to the reduction achieved with daily use of latanoprost eye drops. The contact lens was well-tolerated by all patients, with no adverse effects reported.
One of the advantages of MediPrint’s contact lens is its sustained release of medication. Unlike eye drops, which need to be administered multiple times a day, the contact lens can provide continuous drug delivery for up to a month. This could improve patient compliance with treatment and reduce the risk of missed doses, which can lead to fluctuations in IOP.
Another advantage of the contact lens is its ability to deliver medication directly to the eye. Eye drops can be difficult to administer correctly, and some of the medication may be lost due to blinking or tear drainage. The contact lens ensures that the medication is delivered precisely where it is needed, maximizing its effectiveness.
While the study was small and further research is needed to confirm the results, MediPrint’s contact lens with drug release capability shows promise as a new treatment option for glaucoma patients. The technology could also be adapted to deliver other medications for various eye conditions, potentially revolutionizing the way we treat eye diseases in the future.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- EVM Finance. Unified Interface for Decentralized Finance. Access Here.
- Quantum Media Group. IR/PR Amplified. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...